A Multi-Center Phase II Study to Compare MER-101 (20mg) Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

This study is currently recruiting participants.
Information provided by Merrion Pharmaceuticals, LLC

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Hormone-Refractory Prostate Cancer
2		Additional conditions recognized in this trial
			Prostatic Neoplasms
3		More general conditions related to this trial
			Genital Diseases, Male
			Genital Neoplasms, Male
			Neoplasms
			Neoplasms by Site
			Prostatic Diseases
			Urogenital Neoplasms
4		Interventions listed in this trial
			Zoledronic Acid 20mg Tablets
			Zoledronic Acid
			Zoledronic Acid 20mg Tablets
5		Additional drug interventions recognized in this trial
			Diphosphonates
6		More general drug interventions related to this trial
			Bone Density Conservation Agents
			Pharmacologic Actions
			Physiological Effects of Drugs
7		Sponsors listed in this trial
			Merrion Pharmaceuticals, LLC